



*ՀԳՊԱՄ*

---

**MANAGEMENT OF INNOVATIVE ACTIVITY**

**METHODOLOGICAL RECOMMENDATIONS FOR THE INDIVIDUAL  
WORK OF FOREIGN STUDENTS ON SPECIALTY  
8.12020101 "PHARMACY"**

MINISTRY OF PUBLIC HEALTH OF UKRAINE  
NATIONAL UNIVERSITY OF PHARMACY

O.V. Posilkina, E.V. Litvinova

**MANAGEMENT OF INNOVATIVE ACTIVITY**

Methodological recommendations for the individual work of foreign  
students on specialty 8.12020101 “Pharmacy”

Kharkiv  
NUPh  
2019

UDC 347.77 +347.78

Recommended by CMC of National University of Pharmacy  
(letter № 3 from 13.02.2019)

**Reviewers:** M.V. Zarichkova, Doctor of Pharmacy, associate professor of department of management and economics of pharmacy of institute of pharmacy professionals qualification improvement of National University of Pharmacy; I.V. Bondareva, Candidate of Pharmacy, associate professor of pharmaceutical marketing and management department of the National University of Pharmacy

**O.V. Posilkina, E.V. Litvinova**

Management of innovative activity : method. recommend. for the individual work of foreign students on specialty 8.12020101 “Pharmacy”. – Kharkiv: NUPh, 2019. – 23 p.

Management of innovative activity as an educational discipline is intended to provide knowledge about effective formation and evaluation of innovative activity of the enterprise within the framework of a market economy, laying the foundations for students to study the organization, planning, functions and means of introducing innovations in the enterprise. It is intended to familiarize with the work of innovative structures of modern organizations and their documentary support. This knowledge helps students to benefit from new and innovative ideas and technological capabilities.

**UDC 347.77+347.78**

© Posilkina O.V.,  
Litvinova E.V., 2019  
© NUPh, 2019

## THE CONTENT

<b>Introduction</b>	3
<b>Module 1. <i>MANAGEMENT OF INNOVATIVE ACTIVITY</i></b>	
<b>Individual students' work 1</b>	4
Assignment patent search	
<b>Individual students' work 2</b>	7
Informative patent search	
<b>Individual students' work 3</b>	9
Patent classification systems for effective patent searching	
<b>Control questions</b>	21
<b>Literature</b>	22

## **Introduction**

The vitality and prospects of the economic development of pharmacy in all countries of the world are largely determined by the scale, quality and level of scientific research and the level of technological processes that are being used. Today, the urgent task for the pharmaceutical industry of Ukraine is the transition to an innovative development model that will increase the quantity of modern, high-quality, efficient, safe and affordable medicines in the pharmaceutical market of Ukraine.

Teaching goal of a subject «Management of innovation activity» is learning future specialists to possess theoretical knowledge and practice of managing innovative activities of pharmaceutical enterprises and organizations of various forms of ownership to achieve technological and product leadership, to highlight the special significance of innovations in the field of the production of medicinal products and active pharmaceutical ingredients.

The technical information contained in patent documents can provide future specialists with important insights that may be used to, namely to avoid unnecessary expenses in researching what is already known, identify and evaluate technology for licensing and technology transfer, identify alternative technologies, keep abreast with the latest technologies in your field of expertise, find ready solutions to technical problems, get ideas for further innovation. Patent information would help to locate business partners, locate suppliers and materials, monitor activities of real and potential competitors, identify niche markets. The information contained in patent documents could also be used by future specialists to avoid possible infringement problems, assess patentability of your own inventions, oppose grant of patents wherever they conflict with your own patent.

**Module 1. MANAGEMENT OF INNOVATIVE ACTIVITY****Individual students' work 1****Topic: Assignment patent search****Task 1**

1. Assignment search is to determine legal ownership of a patent. These are searches for locating information about published patent documents involving specific companies or individuals, as applicants, assignees, patentees or inventors. Carry out assignment patent search in accordance with your topic.

**TOPICS:**

1. Astrazeneca, Switzerland
  2. Biogen, USA
  3. Boehringer Ingelheim pharma, Germany
  4. Eli Lilly & Co, USA
  5. Glaxosmithkline, Great Britain
  6. Grindeks, Latvia
  7. Janssen Pharmaceutica, Belgium
  8. Lek Pharmaceutical Company, Slovenia
  9. Lundbeck, Denmark
  10. Merck & Co. Inc, USA
  11. Novartis AG, Switzerland
  12. Panacea Biotec, India
  13. Pfizer Inc, USA
  14. Sanofi-Aventis, France
  15. Schering, USA
  16. Servier, France
2. Use Website *<http://worldwide.espacenet.com>* (European Patent Office) for search purposes. Enter the name of the pharmaceutical company in the field "Applicant".

Настройка ссылок

redir.dll?...

Домой Веб-каналы (0) 4m


**Espacenet**  
 Patent search

Deutsch English Français  
Contact  
Change country ▾

About Espacenet Other EPO online services ▾  
 Search Result list My patents list (0) Query history Settings Help

**SmartSearch**

Quick search  
 Advanced search  
 Number search  
 Classification search

SmartSearch: i Siemens EP 2007

Clear Search

Maintenance news -

**Scheduled maintenance**

Espacenet may have outages on the following dates and times:  
June 29th 17:00-18:00CET  
→ [read more...](#)

News flashes +

Latest updates +

Related links +

Welcome to the new look Espacenet.

Numerically, this is actually version 5 but we don't really know what happened to version 4! Although it looks radically different, Espacenet v.5 delivers the same quality document search service as its predecessor. You'll see that the user interface has been completely redesigned, but this is more than just a cosmetic face-lift. We've also taken the chance to improve the lay-out, usability, ergonomics, and navigation, using contemporary design criteria, in consultation with the user community. You'll also notice the new look Espacenet logo

But new functions and features haven't been forgotten either. In v.5 first release we've included an export-to-Excel function, RSS feeds, breadcrumb navigation, query history, amongst others. These features have been developed and implemented after collecting feedback from you, the users, as always.

For a limited period, v.5 Espacenet will run in parallel with the legacy systems at ep.espacenet.com and v3.espacenet.com, to enable users to become familiar with the new Espacenet v.5. However we expect to turn off the legacy systems in one or two months' time. We recommend that you bookmark the new URLs now. If you're one of the 90% of Espacenet users who access the service directly: <http://worldwide.espacenet.com/> is the URL to remember.

National offices will gradually adopt and customise the new GUI for their own Espacenet instances.

We hope you enjoy searching with the new Espacenet v.5. We thrive on feedback and we'd like to hear yours - tell us what you think about the new Espacenet GUI.

Write to [espacenet@epo.org](mailto:espacenet@epo.org) using the subject GUI

We're waiting to hear from you.

Настройка ссылок

Домой


 Office européen des brevets

About Espacenet Other EPO online services ▾  
 Search Result list My patents list (0) Query history Settings Help

**Advanced search**

**1. Database**

Select the database in which you wish to search: i  
Worldwide - full collection of published patent applications from 80+ countries

**2. Search terms**

Enter keywords in English - ctrl-enter expands the field you are in

Keyword(s) in title: i plastic and bicycle

Keyword(s) in title or abstract: i hair

Publication number: i WO2008014520

Application number: i DE19971031696

Priority number: i WO1995US15925

Publication date: i yyyyymmdd

Applicant(s): i Institut Pasteur  
Bervier

Inventor(s): i Smith

European Classification (ECLA): i F03G7/10

International Patent Classification (IPC): i H03M1/12

Clear Search

Media [Настройка ссылок](#)

[Домой](#) [Веб-каналы \(0\)](#) [Читать по...](#)



**Espacenet**  
 Patent search

Deutsch English Français  
 Contact  
 Change country ▼

← About Espacenet Other EPO online services ▼

Search **Result list** ★ My patents list (0) Query history Settings Help

Search → Results page 1

SmartSearch

Quick search

Advanced search

Number search

Classification search

---

Quick help —

→ Can I subscribe to an RSS feed of the result list?

→ What does RSS reader do with the result list?

→ Can I export the result list?

→ What happens if I click on "Download covers"?

→ Why is the number of results sometimes approximate?

→ Why is the list limited to 500 results?

→ Why could it be that a certain patent document is not displayed in the results list?

→ Can I sort the result list?

→ Why do I sometimes get results having a title which is not in English?

→ What happens if I click on the star icon?

→ What is an XP document?

---

Related links +

### Result list 🔍

Select all  Compact

Approximately 5,808 results found in the Worldwide database for:  
 Servier as the applicant  
 Only the first 500 results are displayed. 1

Results are sorted by date of upload in database

1. UBIQUITIN SPECIFIC PROTEASES RESPONSIBLE FOR MCL-1 STABILITY AND USES THEREOF

★ Inventor:	Applicant:	EC:	IPC:	Publication info:	Priority date:
GENESTE OLIVIER [FR]	SERVIER LAB [FR]	C12Q1/37	A61P35/00	CA2741831 (A1)	2008-10-30
HICKMAN JOHN [FR] (+2)	HYBRIGENICS [FR]	G01N33/50D2B	C12Q1/37 G01N33/50	2010-05-06	

2. Pharmaceutical Composition Comprising a Strontium Salt, Vitamin D and a Cyclodextrin ←

★ Inventor:	Applicant:	EC:	IPC:	Publication info:	Priority date:
BRIAULT GILLES	SERVIER LAB	A61K9/16H6F	A61K31/592	AU2010241527 (A1)	2009-11-27
QUENAULT XAVIER (+2)		A61K9/20H4	A61K31/593 A61K33/24 (+3)	2011-06-16	

3. AZABICYCLO[3.1.0]HEX-2-YL DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

★ Inventor:	Applicant:	EC:	IPC:	Publication info:	Priority date:
GASARA PATRICK [FR]	SERVIER LAB [FR]	C07D209/52	A61K31/403	WO2011070252 (A1)	2009-12-09
CHOLLET ANNE-MARIE [FR] (+4)	GASARA PATRICK [FR] (+5)		C07D209/52 A61P25/00	2011-06-16	

4. AZABICYCLO[3.2.0]HEPT-6-YL DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR

★ Inventor:	Applicant:	EC:	IPC:	Publication info:	Priority date:
GASARA PATRICK [FR]	SERVIER LAB [FR]		A61K31/397	WO2011070252 (A1)	2009-12-09
CHOLLET ANNE-MARIE [FR] (+4)	GASARA PATRICK [FR] (+5)		A61P25/00 C07D205/12	2011-06-16	

Media [Настройка ссылок](#)

[Домой](#) [Веб-к...](#)



**Espacenet**  
 Patent search

Deutsch Er  
 Ch

← About Espacenet Other EPO online services ▼

Search **Result list** ★ My patents list (0) Query history Settings Help

Search → Results page 1 → AU2010241527 (A1)

AU 2010241527 (A1)

**Bibliographic data**

Description

Claims

Mosaics

Original document

INPADOC legal status

---

Quick help —

→ What does A1, A2, A3 and B stand for after a publication number?

→ What happens if I click on "In my patents list"?

→ What happens if I click on the "Register" button?

→ Why are some sidebar options deactivated for certain documents?

→ How can I bookmark this page?

→ Why does a list of documents with the heading "Also published as" sometimes appear, and what are these documents?

→ What is a cited document?

→ What are citing documents?

→ What information will I find if I click on the link "View all"?

→ Why do I sometimes find the abstract of a corresponding document?

→ What happens if I click on the button "Translate this text"?

### Bibliographic data: AU 2010241527 (A1)

★ In my patents list Previous 2 / 500 Next → Report data error

**Pharmaceutical Composition Comprising a Strontium Salt, Vitamin D and a Cyclodextrin**

**Page bookmark** [AU 2010241527 \(A1\) - Pharmaceutical Composition Comprising a Strontium Salt, Vitamin D and](#)

**Publication date:** 2011-06-16

**Inventor(s):** BRIAULT GILLES; QUENAULT XAVIER; POIRIER CECILE; PEAN JEAN-MANUEL ±

**Applicant(s):** [SERVIER LAB](#) ±

**Classification:**

- international: [A61K31/592](#); [A61K31/593](#); [A61K33/24](#); [A61K47/40](#); [A61P19/08](#); [A61P19/10](#)

- European: [A61K9/16H6F](#); [A61K9/20H4](#); [A61K9/20H4B](#); [A61K9/20H6F](#)

**Application number:** AU20100241527 20101118

**Priority number(s):** FR20090005706 20091127

**Abstract not available for AU 2010241527 (A1)**

3. Find 10 patents in accordance with your topic. Obtain information on the validity (status) of a patent or a published patent application, on the given date, under the applicable patent legislation in one or more countries. Such information can assist in making decisions on, for example, exporting, or in the negotiation of license agreements.

### **Task 2**

Write the assignment patent search report:

Topic\_\_\_\_\_

Date\_\_\_\_\_

Websites\_\_\_\_\_

N	Serial № of patent Country of publication	Applicant, Date of application	The validity (status) of a patent	Abstract of the invention

## **Individual students' work 2**

### **Topic: Informative patent search**

#### **Task 1**

1. Informative search is made to determine the general state-of-the-art for the solution of the given technical problem as background information for R&D activities and in order to know what patent publications already exist in the field of technology or research. Further reasons for undertaking this kind of search could be the wish to identify alternative technologies, which may replace known technology or to evaluate a specific technology, which is being offered for licensing or which is being considered for acquisition. Carry out informative patent search in accordance with your topic.

#### **TOPICS:**

- |                    |                       |
|--------------------|-----------------------|
| 1. Acetylcysteine  | 6. Arginine glutamate |
| 2. Aciclovir       | 7. Atorvastatin       |
| 3. Alendronic acid | 8. Beclometasone      |
| 4. Amlodipine      | 9. Betahistine        |
| 5. Amoxicillin     | 10. Betamethasone     |

- |     |                |     |               |
|-----|----------------|-----|---------------|
| 11. | Candesartan    | 25. | Metformin     |
| 12. | Celecoxib      | 26. | Miconazole    |
| 13. | Dalteparin     | 27. | Omeprazole    |
| 14. | Enoxaparin     | 28. | Orlistat      |
| 15. | Esomeprazol    | 29. | Pantoprazole  |
| 16. | Ethambutol     | 30. | Perindopril   |
| 17. | Glibenclamide  | 31. | Rifampicin    |
| 18. | Ipratropium    | 32. | Terbinafine   |
| 19. | Isoniazid      | 33. | Tioctic acid  |
| 20. | Ketorolac      | 34. | Trimetazidine |
| 21. | Lactulose      | 35. | Vardenafil    |
| 22. | Lamivudine     | 36. | Zidovudine    |
| 23. | Levocetirizine | 37. | Zolmitriptan  |
| 24. | Loratadine     | 38. | Zopiclone     |

2. Use Website *http://ep.espacenet.com* (*European Patent Office*) for search purposes. Enter international nonproprietary names of a drug in the field “Keyword(s) in title or abstract”.

3. Identify companies and/or inventors who are active in a specific field of pharmacy according with your topic.

4. Carry out “Infringement Search”. Locate patents and published patent applications, which might be infringed on by a given industrial activity.

5. Carry out “Patent Family Searches”. Find a “patent family member” that is written in a desired language. Estimate the importance of the invention (by number of patent documents relating to the same invention and being published in different countries or by industrial property organizations).

## **Task 2**

Write the informative patent search report (10 patents)

Topic\_\_\_\_\_

Date\_\_\_\_\_

Websites\_\_\_\_\_

N	Serial № of patent Country of publication	Applicant, Date of application	The validity (status) of a patent	Patent family member	Abstract of the invention

### Task 3

Use Website <http://www.ncbi.nlm.nih.gov/pubmed> (U.S. National Library of Medicine National Institutes of Health) for search purposes. Find information of clinical trials of drugs according to the topic (10 abstract).

### Individual students' work 3

#### Topic: Patent classification systems for effective patent searching

#### Task 1

1. Carry out patent search in accordance with your topic.

#### TOPICS:

1. Drugs for ulcers, gastritis or reflux esophagitis
2. Stomatological medicines
3. Drugs for liver or gallbladder disorders
4. Drugs for pancreatic disorders, e.g. pancreatic enzymes
5. Drugs for hyperglycaemia, e.g. antidiabetics
6. Vitamins
7. Drugs for calcium homeostasis
8. Immunomodulators
9. Antiallergic agents
10. Drugs for urolithiasis
11. Antithrombotic agents
12. Drug for joint disorders, e.g. arthritis, arthrosis
13. Sedatives
14. Antimycotics
15. Mucolytics
16. Antiasthmatic agents
17. Drugs for treating wounds, ulcers, burns, scars, keloids, or the like
18. Drugs of the kidneys
19. Drugs for cataracts
20. Antihypertensives
21. Capillary stabilizers
22. Antipsoriatics

- |   |                          |
|---|--------------------------|
| 23. Antihyperlipidemics   | 27. Anaesthetics         |
| 24. Drugs for disorders of the respiratory system, nasal agents         | 28. Anti-Parkinson drugs |
| 25. Drugs for disorders of the respiratory system, for throat disorders | 29. Otologicals          |
| 26. Antimigraine agents   | 30. Antiglaucoma agents  |
|   | 31. Antidepressants      |
|   | 32. Antiemetics          |
|   | 33. Antidiarrhoeals      |

2. Before making the search, a student should to identify the proper place for a subject of search in the International Patent Classification.

***A61P Specific therapeutic activity of chemical compounds  
or medicinal preparations***

A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system [7]

A61P 1/02 · Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis [7]

A61P 1/04 · For ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants [7]

A61P 1/06 · Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia [7]

A61P 1/08 · For nausea, cinetosis or vertigo; Antiemetics [7]

A61P 1/10 · Laxatives [7]

A61P 1/12 · Antidiarrhoeals [7]

A61P 1/14 · Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antifatulents [7]

A61P 1/16 · For liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics [7]

A61P 1/18 · For pancreatic disorders, e.g. pancreatic enzymes [7]

A61P 3/00 Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) [7]

A61P 3/02 · Nutrients, e.g. vitamins, minerals [7]

- A61P 3/04· Anorexiant; Antiobesity agents [7]
- A61P 3/06· Antihyperlipidemics [7]
- A61P 3/08· For glucose homeostasis (pancreatic hormones A61P 5/48) [7]
- A61P 3/10· · For hyperglycaemia, e.g. antidiabetics [7]
- A61P 3/12· For electrolyte homeostasis [7]
- A61P 3/14· · For calcium homeostasis (vitamin D A61P 3/02; parathyroid hormones A61P 5/18; calcitonin A61P 5/22; osteoporosis A61P 19/10; bone metastasis A61P 35/04) [7]
- A61P 5/00 Drugs for disorders of the endocrine system [7]
- A61P 5/02· Of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin [7]
- A61P 5/04· · For decreasing, blocking or antagonising the activity of the hypothalamic hormones [7]
- A61P 5/06· Of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH [7]
- A61P 5/08· · For decreasing, blocking or antagonising the activity of the anterior pituitary hormones [7]
- A61P 5/10· Of the posterior pituitary hormones, e.g. oxytocin, ADH [7]
- A61P 5/12· · For decreasing, blocking or antagonising the activity of the posterior pituitary hormones [7]
- A61P 5/14· Of the thyroid hormones, e.g. T3, T4 [7]
- A61P 5/16· · For decreasing, blocking or antagonising the activity of the thyroid hormones [7]
- A61P 5/18· Of the parathyroid hormones [7]
- A61P 5/20· · For decreasing, blocking or antagonising the activity of PTH [7]
- A61P 5/22· · For decreasing, blocking or antagonising the activity of calcitonin [7]
- A61P 5/24· Of the sex hormones [7]
- A61P 5/26· · Androgens [7]
- A61P 5/28· · Antiandrogens [7]
- A61P 5/30· · Oestrogens [7]

A61P 5/32· · Antioestrogens [7]

A61P 5/34· · Gestagens [7]

A61P 5/36· · Antigestagens [7]

A61P 5/38· Of the suprarenal hormones [7]

A61P 5/40· · Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids [7]

A61P 5/42· · For decreasing, blocking or antagonising the activity of mineralocorticosteroids [7]

A61P 5/44· · Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids [7]

A61P 5/46· · For decreasing, blocking or antagonising the activity of glucocorticosteroids [7]

A61P 5/48· Of the pancreatic hormones [7]

A61P 5/50· · For increasing or potentiating the activity of insulin [7]

A61P 7/00 Drugs for disorders of the blood or the extracellular fluid [7]

A61P 7/02· Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors [7]

A61P 7/04· Antihæmorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents [7]

A61P 7/06· Antianaemics [7]

A61P 7/08· Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04) [7]

A61P 7/10· Antioedematous agents; Diuretics [7]

A61P 7/12· Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10) [7]

A61P 9/00 Drugs for disorders of the cardiovascular system [7]

A61P 9/02· Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives [7]

A61P 9/04· Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure [7]

A61P 9/06· Antiarrhythmics [7]

A61P 9/08· Vasodilators for multiple indications [7]

A61P 9/10· For treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis [7]

A61P 9/12· Antihypertensives [7]

A61P 9/14· Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers [7]

A61P 11/00 Drugs for disorders of the respiratory system [7]

A61P 11/02· Nasal agents, e.g. decongestants [7]

A61P 11/04· for throat disorders [7]

A61P 11/06· Antiasthmatics [7]

A61P 11/08· Bronchodilators [7]

A61P 11/10· Expectorants [7]

A61P 11/12· Mucolytics [7]

A61P 11/14· Antitussive agents [7]

A61P 11/16· Central respiratory analeptics [7]

A61P 13/00 Drugs for disorders of the urinary system (diuretics A61P 7/10) [7]

A61P 13/02· Of urine or of the urinary tract, e.g. urine acidifiers [7]

A61P 13/04· For urolithiasis [7]

A61P 13/06· Anti-spasmodics [7]

A61P 13/08· Of the prostate [7]

A61P 13/10· Of the bladder [7]

A61P 13/12· Of the kidneys [7]

A61P 15/00 Drugs for genital or sexual disorders (for disorders of sex hormones

A61P 5/24); Contraceptives [7]

A61P 15/02· For disorders of the vagina [7]

A61P 15/04· For inducing labor or abortion; Uterotonics [7]

A61P 15/06· Antiabortive agents; Labor repressants [7]

- A61P 15/08· For gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis [7]
- A61P 15/10· For impotence [7]
- A61P 15/12· For climacteric disorders [7]
- A61P 15/14· For lactation disorders, e.g. galactorrhoea [7]
- A61P 15/16· Masculine contraceptives [7]
- A61P 15/18· Feminine contraceptives [7]
- A61P 17/00 Drugs for dermatological disorders [7]
- A61P 17/02· For treating wounds, ulcers, burns, scars, keloids, or the like [7]
- A61P 17/04· Antipruritics [7]
- A61P 17/06· Antipsoriatics [7]
- A61P 17/08· Antiseborrheics [7]
- A61P 17/10· Anti-acne agents [7]
- A61P 17/12· Keratolytics, e.g. wart or anti-corn preparations [7]
- A61P 17/14· For baldness or alopecia [7]
- A61P 17/16· Emollients or protectives, e.g. against radiation [7]
- A61P 17/18· Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00) [8]
- A61P 19/00 Drugs for skeletal disorders [7]
- A61P 19/02· For joint disorders, e.g. arthritis, arthrosis [7]
- A61P 19/04· For non-specific disorders of the connective tissue [7]
- A61P 19/06· Antigout agents, e.g. antihyperuricemic or uricosuric agents [7]
- A61P 19/08· For bone diseases, e.g. rachitism, Paget's disease [7]
- A61P 19/10· · For osteoporosis [7]
- A61P 21/00 Drugs for disorders of the muscular or neuromuscular system [7]
- A61P 21/02· Muscle relaxants, e.g. for tetanus or cramps [7]
- A61P 21/04· For myasthenia gravis [7]
- A61P 21/06· Anabolic agents (androgens A61P 5/26) [7]
- A61P 23/00 Anaesthetics [7]
- A61P 23/02· Local anaesthetics [7]

- A61P 25/00 Drugs for disorders of the nervous system [7]
- A61P 25/02· For peripheral neuropathies [7]
- A61P 25/04· Centrally acting analgesics, e.g. opioids [7]
- A61P 25/06· Antimigraine agents [7]
- A61P 25/08· Antiepileptics; Anticonvulsants [7]
- A61P 25/10· · For petit-mal [7]
- A61P 25/12· · For grand-mal [7]
- A61P 25/14· For treating abnormal movements, e.g. chorea, dyskinesia [7]
- A61P 25/16· · Anti-Parkinson drugs [7]
- A61P 25/18· Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia [7]
- A61P 25/20· Hypnotics; Sedatives [7]
- A61P 25/22· Anxiolytics [7]
- A61P 25/24· Antidepressants [7]
- A61P 25/26· Psychostimulants, e.g. nicotine, cocaine [7]
- A61P 25/28· For treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia [7]
- A61P 25/30· For treating abuse or dependence [7]
- A61P 25/32· · Alcohol-abuse [7]
- A61P 25/34· · Tobacco-abuse [7]
- A61P 25/36· · Opioid-abuse [7]
- A61P 27/00 Drugs for disorders of the senses [7]
- A61P 27/02· Ophthalmic agents [7]
- A61P 27/04· · Artificial tears; Irrigation solutions [7]
- A61P 27/06· · Antiglaucoma agents or miotics [7]
- A61P 27/08· · Mydriatics or cycloplegics [7]
- A61P 27/10· · For accommodation disorders, e.g. myopia [7]
- A61P 27/12· · For cataracts [7]
- A61P 27/14· · Decongestants or antiallergics [7]
- A61P 27/16· Otologicals [7]

- A61P 29/00 Non-central analgesic, antipyretic or anti-inflammatory agents, e.g. antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs) [7]
- A61P 29/02· Without anti-inflammatory effect [7]
- A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics [7]
- A61P 31/02· Local antiseptics [7]
- A61P 31/04· Antibacterial agents [7]
- A61P 31/06· · For tuberculosis [7]
- A61P 31/08· · For leprosy [7]
- A61P 31/10· Antimycotics [7]
- A61P 31/12· Antivirals [7]
- A61P 31/14· · For RNA viruses [7]
- A61P 31/16· · · For influenza or rhinoviruses [7]
- A61P 31/18· · · For HIV [7]
- A61P 31/20· · For DNA viruses [7]
- A61P 31/22· · · For herpes viruses [7]
- A61P 33/00 Antiparasitic agents [7]
- A61P 33/02· Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis [7]
- A61P 33/04· · Amoebicides [7]
- A61P 33/06· · Antimalarials [7]
- A61P 33/08· · For *Pneumocystis carinii* [7]
- A61P 33/10· Anthelmintics [7]
- A61P 33/12· · Schistosomicides [7]
- A61P 33/14· Ectoparasiticides, e.g. scabicides [7]
- A61P 35/00 Antineoplastic agents [7]
- A61P 35/02· Specific for leukemia [7]
- A61P 35/04· Specific for metastasis [7]
- A61P 37/00 Drugs for immunological or allergic disorders [7]
- A61P 37/02· Immunomodulators [7]
- A61P 37/04· · Immunostimulants [7]
- A61P 37/06· · Immunosuppressants, e.g. drugs for graft rejection [7]

A61P 37/08· Antiallergic agents (antiasthmatic agents A61P 11/06; ophthalmic antiallergics A61P 27/14) [7]

A61P 39/00 General protective or antinoxious agents [7]

A61P 39/02· Antidotes [7]

A61P 39/04· Chelating agents [7]

A61P 39/06· Free radical scavengers or antioxidants [7]

A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution [7]

A61P 43/00 Drugs for specific purposes, not provided for in groups A61P 1/00-A61P 41/00 [7]

### 3. Use Websites for patent searching

#### **Addresses of web sites of foreign intellectual property offices and international organizations**

<b>Code ST.3</b>	<b>Country / Organization</b>	<b>Internet Address</b>
1	2	3
AD	Andorra	<a href="http://www.ompa.ad">http://www.ompa.ad</a>
AM	Armenia	<a href="http://www.armpatent.org">http://www.armpatent.org</a>
AR	Argentina	<a href="http://www.inpi.gov.ar">http://www.inpi.gov.ar</a>
AT	Austria	<a href="http://www.patentamt.at/">http://www.patentamt.at/</a>
AU	Australia	<a href="http://www.ipaustralia.gov.au/">http://www.ipaustralia.gov.au/</a> <a href="http://www.ag.gov.au">http://www.ag.gov.au</a>
AZ	Azerbaijan Republic	<a href="http://www.azpat.org">http://www.azpat.org</a>
BA	Bosnia and Herzegovina	<a href="http://www.basmp.gov.ba/index.htm">http://www.basmp.gov.ba/index.htm</a>
BB	Barbados	<a href="http://www.caipo.gov.bb">http://www.caipo.gov.bb</a>
BE	Belgium	<a href="http://economie.fgov.be/fr/entreprises/propriete_intellectuelle/index.jsp">http://economie.fgov.be/fr/entreprises/propriete_intellectuelle/index.jsp</a>
BE	The Belgian Coordinated Collection of Micro-organisms (BCCM™)	<a href="http://www.belspo.be/bccm">http://www.belspo.be/bccm</a>
BG	Bulgaria	<a href="http://www.bpo.bg/">http://www.bpo.bg/</a> <a href="http://www.nbimcc.hit.bg">http://www.nbimcc.hit.bg</a>
BO	Bolivia	<a href="http://www.senapi.gov.bo">http://www.senapi.gov.bo</a>
BR	Brazil	<a href="http://www.inpi.gov.br">http://www.inpi.gov.br</a> <a href="http://www.minc.gov.br">http://www.minc.gov.br</a> ©
BX	Benelux Office	<a href="http://www.bmb-bbm.org">http://www.bmb-bbm.org</a>

1	2	3
BY	Republic of Byelorussia	<a href="http://www.belgopatent.org">http://www.belgopatent.org</a>
BY	CIS Executive Committee	<a href="http://www.cis.minsk.by">http://www.cis.minsk.by</a>
BZ	Belize	<a href="http://www.belipo.bz">http://www.belipo.bz</a>
CA	Canada	<a href="http://opic.gc.ca/">http://opic.gc.ca/</a>
CH	Switzerland	<a href="http://www.ige.ch">http://www.ige.ch</a>
CL	Chile	<a href="http://www.dpi.cl">http://www.dpi.cl</a>
CN	China	<a href="http://www.sipo.gov.cn">http://www.sipo.gov.cn</a> <a href="http://sbj.saic.gov.cn">http://sbj.saic.gov.cn</a> <a href="http://www.ncac.gov.cn">http://www.ncac.gov.cn</a> ©
CR	Costa Rica	<a href="http://www.registronacional.go.cr">http://www.registronacional.go.cr</a>
CU	Cuba	<a href="http://www.ocpi.cu">http://www.ocpi.cu</a>
CY	Cyprus	<a href="http://www.mcit.gov.cy/drcor">http://www.mcit.gov.cy/drcor</a>
CZ	Czech Republic	<a href="http://www.upv.cz">http://www.upv.cz</a>
DE	Germany	<a href="http://www.deutsches-patentamt.de">http://www.deutsches-patentamt.de</a> <a href="http://www.dpma.de">http://www.dpma.de</a>
DK	Denmark	<a href="http://www.dkpto.dk">http://www.dkpto.dk</a>
DO	Dominican Republic	<a href="http://www.seic.gov.do/onapi">http://www.seic.gov.do/onapi</a>
DZ	Algeria	<a href="http://www.inapi.org">http://www.inapi.org</a>
EA	Eurasian Patent Office	<a href="http://www.eapo.org">http://www.eapo.org</a>
EE	Estonia	<a href="http://www.epa.ee">http://www.epa.ee</a>
EG	Egypt	<a href="http://www.egypo.gov.eg">http://www.egypo.gov.eg</a>
EM	Internal Market Harmonization Office (EU Trademarks)	<a href="http://oami.eu.int/">http://oami.eu.int/</a>
EP	European Patent Office	<a href="http://www.european-patent-office.org">http://www.european-patent-office.org</a>
ES	Spain	<a href="http://www.oepm.es">http://www.oepm.es</a> <a href="http://www.mcu.es/Propiedad_Intelectual/indice.htm">http://www.mcu.es/Propiedad_Intelectual/indice.htm</a> ©
FI	Finland	<a href="http://www.prh.fi">http://www.prh.fi</a> <a href="http://www.minedu.fi">http://www.minedu.fi</a> ©
FR	France	<a href="http://www.inpi.fr">http://www.inpi.fr</a> <a href="http://www.ieepi.org/">http://www.ieepi.org/</a>
GB	Great Britain	<a href="http://www.patent.gov.uk">http://www.patent.gov.uk</a> <a href="http://www.intellectual-property.gov.uk/">http://www.intellectual-property.gov.uk/</a>
GC	The Patent Office for the Cooperation Council for the Arab States of the Gulf	<a href="http://www.gccpo.org/e-index.htm">http://www.gccpo.org/e-index.htm</a>
GE	Georgia	<a href="http://www.sakpatenti.org.ge">http://www.sakpatenti.org.ge</a>
GR	Greece	<a href="http://www.european-patent-office.org/patlib/country/greece/index.htm">http://www.european-patent-office.org/patlib/country/greece/index.htm</a> <a href="http://www.obl.gr">http://www.obl.gr</a>

1	2	3
HK	Hong-Kong (Special Administrative District of the Peoples Republic of China)	<a href="http://www.info.gov.hk/ipd">http://www.info.gov.hk/ipd</a>
HR	Croatia	<a href="http://www.dziv.hr">http://www.dziv.hr</a>
HU	Hungary	<a href="http://www.hpo.hu">http://www.hpo.hu</a> <a href="http://ncaim.kee.hu/">http://ncaim.kee.hu/</a>
ID	Indonesia	<a href="http://www.dgip.go.id">http://www.dgip.go.id</a>
IE	Ireland	<a href="http://www.patentsoffice.ie">http://www.patentsoffice.ie</a> <a href="http://www.entemp.ie">http://www.entemp.ie</a>
IL	Israel	<a href="http://www.patents.gov.il">http://www.patents.gov.il</a>
IN	India	<a href="http://www.patentoffice.nic.in">http://www.patentoffice.nic.in</a> <a href="http://ipindia.nic.in">http://ipindia.nic.in</a>
IS	Iceland	<a href="http://www.patent.is">http://www.patent.is</a>
IT	Italy	<a href="http://www.uibm.gov.it/">http://www.uibm.gov.it/</a>
JM	Jamaica	<a href="http://www.jipo.gov.jm">http://www.jipo.gov.jm</a>
JO	Jordan	<a href="http://www.mit.gov.jo">http://www.mit.gov.jo</a>
JP	Japan	<a href="http://www.jpo.go.jp">http://www.jpo.go.jp</a>
KG	Kirghizstan	<a href="http://www.kyrgyzpatent.org">http://www.kyrgyzpatent.org</a>
KR	Republic of Korea	<a href="http://www.kipo.go.kr/eng/">http://www.kipo.go.kr/eng/</a>
KZ	Kazakhstan	<a href="http://www.kazpatent.kz">http://www.kazpatent.kz</a> <a href="http://www.intellkaz.kz">http://www.intellkaz.kz</a> <a href="http://www.kazpatent.org">http://www.kazpatent.org</a>
LA	Lao People's Democratic Republic	<a href="http://www.stea.la.wipo.net/index.html">http://www.stea.la.wipo.net/index.html</a>
LB	Lebanon	<a href="http://www.economy.gov.lb">http://www.economy.gov.lb</a>
LT	Lithuania	<a href="http://www.is.lt/vpb/engl">http://www.is.lt/vpb/engl</a> <a href="http://www.vpb.gov.lt/en/">http://www.vpb.gov.lt/en/</a>
LU	Luxembourg	<a href="http://www.eco.public.lu/attributions/dg2/index.html">http://www.eco.public.lu/attributions/dg2/index.html</a>
LV	Latvia	<a href="http://www.lrvp.lv">http://www.lrvp.lv</a>
MA	Morocco	<a href="http://www.ompic.org.ma">http://www.ompic.org.ma</a>
MC	Monaco	<a href="http://www.european-patent-office.org/patlib/country/monaco">http://www.european-patent-office.org/patlib/country/monaco</a>
MD	Republic of Moldova	<a href="http://www.agepi.md">http://www.agepi.md</a>
MK	FYR Macedonia	<a href="http://www.ippo.gov.mk">http://www.ippo.gov.mk</a>
MN	Mongolia	<a href="http://www.ipom.mn">http://www.ipom.mn</a>
MO	Macao	<a href="http://www.economia.gov.mo">http://www.economia.gov.mo</a>
MX	Mexico	<a href="http://www.impi.gob.mx">http://www.impi.gob.mx</a>
MY	Malaysia	<a href="http://mipc.gov.my">http://mipc.gov.my</a>
MZ	Mozambique	<a href="http://www.ipi.gov.mz/">http://www.ipi.gov.mz/</a>
NE	Niger	<a href="http://www.bnda.ne.wipo.net">http://www.bnda.ne.wipo.net</a>
NL	The Netherlands	<a href="http://www.octrooicentrum.nl">http://www.octrooicentrum.nl</a>
NO	Norway	<a href="http://www.patentstyret.no">http://www.patentstyret.no</a> <a href="http://www.dep.no/kd">http://www.dep.no/kd</a> ©
NP	Nepal	<a href="http://www.ip.np.wipo.net">http://www.ip.np.wipo.net</a>
NZ	New Zealand	<a href="http://www.iponz.govt.nz">http://www.iponz.govt.nz</a>

1	2	3
PE	Peru	<a href="http://www.indecopi.gob.pe/">http://www.indecopi.gob.pe/</a>
PH	Philippines	<a href="http://www.ipophil.gov.ph">http://www.ipophil.gov.ph</a>
PL	Poland	<a href="http://www.uprp.pl">http://www.uprp.pl</a>
PT	Portugal	<a href="http://www.inpi.pt">http://www.inpi.pt</a>
RO	Romania	<a href="http://www.osim.ro">http://www.osim.ro</a>
RS	Serbia	<a href="http://www.zic.gov.rs">http://www.zic.gov.rs</a>
RU	Russia	<a href="http://www.rupto.ru">http://www.rupto.ru</a>
SE	Sweden	<a href="http://www.prv.se">http://www.prv.se</a>
SG	Singapore	<a href="http://www.ipos.gov.sg">http://www.ipos.gov.sg</a>
SI	Slovenia	<a href="http://www.uil-sipo.si">http://www.uil-sipo.si</a>
SK	Slovakia	<a href="http://www.upv.sk">http://www.upv.sk</a>
SM	San Marino	<a href="http://www.usbm.sm/">http://www.usbm.sm/</a>
TH	Thailand	<a href="http://www.ipthailand.org">http://www.ipthailand.org</a>
TJ	Tadjikistan	<a href="http://www.tjpat.org">http://www.tjpat.org</a>
TM	Turkmenistan	<a href="http://www.tmpatent.org">http://www.tmpatent.org</a>
TN	Tunisia	<a href="http://www.inorpi.ind.tn">http://www.inorpi.ind.tn</a>
TR	Turkey	<a href="http://www.turkpatent.gov.tr">http://www.turkpatent.gov.tr</a>
UA	Ukraine	<a href="http://www.sdip.gov.ua">http://www.sdip.gov.ua</a> <a href="http://www.ukrpatent.org/">http://www.ukrpatent.org/</a>
US	International Trademark Association (INTA)	<a href="http://www.inta.org/">http://www.inta.org/</a>
US	United States of America	<a href="http://www.uspto.gov">http://www.uspto.gov</a> <a href="http://www.loc.gov/copyright">http://www.loc.gov/copyright</a> ©
UY	Uruguay	<a href="http://dnpi.gub.uy">http://dnpi.gub.uy</a>
UZ	Uzbekistan	<a href="http://www.patent.uz">http://www.patent.uz</a>
VC	Saint Vincent and the Grenadines	<a href="http://www.gov.vc/govt/cipo/index.asp">http://www.gov.vc/govt/cipo/index.asp</a>
WO	WIPO	<a href="http://www.wipo.int/">http://www.wipo.int/</a>

4. Find 10 patents in accordance with your topic

### Task 2

Write the patent search report

Topic \_\_\_\_\_

Date \_\_\_\_\_

Websites \_\_\_\_\_

N	Serial № of patent, country of publication	Classification symbols	The title of the invention, applicant names	Abstract of the invention

## CONTROL QUESTIONS

1. The urgency of innovation activity to ensure the competitiveness of the pharmaceutical company.
2. The essence of innovation and innovation of the enterprise. Classification of innovations in pharmacy.
3. Functions of management of innovative activity.
4. Regulatory of innovation activity.
5. Essence of planning of innovation activity.
6. Innovative organizational structures and their classification.
7. Organizational construction of an innovative organization.
8. Essence and classification of innovative risks.
9. Classification of sources of financing for innovation activities.
10. Forms of indirect financing of innovation activity.
11. Venture capital and venture entrepreneurship.
12. Composition and structure of innovation costs.
13. Understanding and essence of the innovation project.
14. Procedure for development and implementation of the innovation project.
15. Analysis and selection of innovative projects.
16. Effect and effectiveness of innovation.
17. Methods of evaluating the effectiveness of innovative projects.
18. Actuality of state regulation of innovation activity in market conditions.
19. Foreign experience of state regulation of innovation activity.
20. Ways to commercialize intellectual property.
21. Intellectual property in pharmacy.
22. International Patent Classification (IPC).

## Literature

1. Економіка та організація інноваційної діяльності : навч. посіб. / С. І. Шерстобітов [та ін.]. – Х. : ХНАДУ, 2013. – 340 с.
2. Посилкіна, О. В. Управління інноваційною діяльністю : навч. посіб. для студ. вищ. навч. закладів / О. В. Посилкіна, О. В. Літвінова, Ю. С. Братішко. – Х. : НфаУ, 2018. – 270 с.
3. Посилкіна, О. В. Інноваційний розвиток підприємства : конспект лекцій для студентів економічних спеціальностей / О. В. Посилкіна, Ю. С. Братішко, Г. В. Кубасова. – Х. : НФаУ, 2015. – 276 с.
4. Про інноваційну діяльність [Електронний ресурс] : закон України від 04.07.2002 р. № 40–IV, із змінами та доповненнями. – Режим доступу: <http://zakon.rada.gov.ua> (дата звернення: 06.02.2019). - Заголовок з екрану.
5. Про лікарські засоби [Електронний ресурс] : закон України від 04.04.96 р. № 124-96 із змінами та доповненнями. – Режим доступу: <http://zakon.rada.gov.ua> (дата звернення: 06.02.2019). - Заголовок з екрану.
6. Про охорону прав на винаходи і корисні моделі [Електронний ресурс] : закон України від 15.12.93 р. № 3687-ХІІ, із змінами та доповненнями. – Режим доступу: <http://zakon.rada.gov.ua> (дата звернення: 06.02.2019). - Заголовок з екрану.
7. Agreement on trade-related aspects of intellectual property rights (TRIPS) [Electronic resource] – Available at: [https://www.wto.org/english/docs\\_e/legal\\_e/27-trips\\_01\\_e.htm](https://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm) (accessed: 06.02.2019).
8. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [Electronic resource]. – Available at: <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm> (accessed: 07.02.2018).
9. Posylkina, O. V. Patent science: Manual (abstract of lectures) for foreign students in speciality 8.110201 “Pharmacy” / O. V. Posylkina, E. V. Litvinova. – Kharkiv : NUPh, 2012. – 164 p.

Методичні рекомендації дають змогу засвоїти теорію і практику управління інноваціями на підприємстві, опанувати стратегію і тактику інноваційного забезпечення підприємства, оволодіти навичками розробки оптимальних інноваційних рішень, особливостями інновацій в галузі виробництва лікарських засобів й активних фармацевтичних інгредієнтів.

Методичні рекомендації призначені для проведення самостійної роботи з дисципліни «Управління інноваційною діяльністю».

Навчальне видання

**Посилкіна** Ольга Вікторівна

**Літвінова** Олена Вячеславна

## **MANAGEMENT OF INNOVATIVE ACTIVITY**

*Methodological recommendations for the individual work of foreign students on specialty 8.12020101 "Pharmacy"*

Англійською мовою

Формат 60x84/16. Ум. друк. арк. 4. Тираж \_\_\_\_\_ пр. Зам. № \_\_\_\_\_.

Національний фармацевтичний університет

вул. Пушкінська, 53, м. Харків, 61002

Свідоцтво суб'єкта видавничої справи серії ДК № 3420 від 11.03.2009.

Надруковано з готових оригінал-макетів у друкарні ФОП Азамаєв В.Р.

Єдиний державний реєстр юридичних осіб та фізичних осіб-підприємців.

Запис № 24800170000026884 від 25.11.1998 р.

Свідоцтво про внесення суб'єкта видавничої справи до державного реєстру видавців, виготівників і розповсюджувачів видавничої продукції.

Серія ХК № 135 від 23.02.05 р.

м. Харків, вул. Познанська 6, к. 84, тел. **(057) 362-01-52**

**e-mail:bookfabrik@rambler.ru**